Solutions

One engine, four kinds of decision

Clinical pharmacology, clinical development, drug safety and research partners ask different questions. They all use the same virtual patients and the same evidence record.

Clinical pharmacology and MIDD

Choose the dose with the whole population in view

Sweep dose and schedule across a realistic cohort, see exposure and response by subgroup, and document the reasoning for your MIDD package.

  • Population exposure and response with intervals
  • Subgroup effects for age, organ function and genotype
  • Surrogates checked against your reference models
Example dose sweepExample

SZ-0412 · 20, 40, 60 mg

20 mg ORR
19% (16–23%)
40 mg ORR
31% (27–35%)
60 mg ORR
34% (30–38%)
60 mg grade 3+ AE
15% (12–18%)
Example. Values are illustrative.

Clinical development

Rank protocols before the first site opens

Protova searches design options and shows which ones keep power while staying safe and inclusive, with the trade-offs written down.

  • Ranked designs with stated trade-offs
  • Sample size and power under realistic heterogeneity
  • Inclusion criteria tested for equity
Example shortlistExample

Phase 2b · 3 designs

Design A
40 mg, n = 180, power 86%
Design B
40 mg, n = 150, power 79%
Design C
20/40 mg, n = 210, power 84%
Example. Values are illustrative.

Drug safety and pharmacovigilance

Look for rare risk where it hides

Vigila oversamples the subgroups that small trials miss and maps where predicted adverse-event risk concentrates.

  • Rare-subgroup stress tests
  • Exposure thresholds for monitoring plans
  • Signals tracked against later outcomes in Evidra
Example signalExample

Hepatic grade 3+

Overall
0.4%
At-risk cluster
3.1%
Cluster share of cohort
1.2%
Example. Values are illustrative.

CROs and academic medical centres

Add simulation to the studies you run

Offer sponsors simulation-backed design work, or use Sanenza for research on under-represented populations.

  • Per-study access for sponsor work
  • Research access for academic groups (planned)
  • Shared evidence records with sponsor approval
Example engagementExample

Sponsor study support

Scope
One protocol, two questions
Duration
8 weeks
Deliverable
Design report and back-test
Example. Values are illustrative.

Compare

Which products each team uses first

TeamFirst questionProductsTypical first output
Clinical pharmacologyWhich dose and schedule?Cohorta, Insilon, EvidraDose sweep with subgroup effects
Clinical developmentWhich protocol?Protova, Insilon, VigilaRanked design shortlist
Drug safetyWhere is the rare risk?Vigila, CohortaSignal map and thresholds
Device and deliveryWhere does the drug go?Physova, InsilonRegional exposure map
CROs and academiaHow do we add simulation?Any, by studyStudy-specific report

Start with your team's first question

Each briefing is built around one decision your team faces, so you can judge the method quickly.